<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440310</url>
  </required_header>
  <id_info>
    <org_study_id>LSO-OL006</org_study_id>
    <nct_id>NCT00440310</nct_id>
  </id_info>
  <brief_title>Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases</brief_title>
  <official_title>A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Treating Colorectal Cancer Patients With Recurrent Liver Metastases Using the Litx™ System Plus Chemotherapy as Compared to Chemotherapy Only</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Light Sciences Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Light Sciences Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the overall survival and progression free survival of
      patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of
      Colorectal Cancer with recurrent liver metastases, and to demonstrate the safety of Litx™
      therapy.

      Litx™ consists of a light-activated drug, talaporfin sodium (LS11, Light Sciences Oncology,
      Bellevue, Washington), and a light generating device, composed of light-emitting diodes
      (LEDs), that is energized by a power controller and percutaneously placed in the target tumor
      tissue inside the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, stratified, two arm study:

        -  Litx™ and chemotherapy arm (FOLFOX4 or FOLFIRI)

        -  Chemotherapy only arm (FOLFOX4 or FOLFIRI)

      For patients who have progressed on FOLFIRI, they will be treated with Litx™ plus FOLFOX4
      versus FOLFOX4 alone; and for patients who have progressed on FOLFOX, they will be treated
      with Litx™ plus FOLFIRI versus FOLFIRI alone.

      Stratification upon enrollment by chemotherapy and tumor sum of the longest diameter (SLD)
      (SLD &lt; 4 cm or SLD ≥4 cm but ≤7.5 cm).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 184 weeks</time_frame>
    <description>Time from randomization to death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">483</enrollment>
  <condition>Liver Metastases</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Neoplasm Recurrence, Local</condition>
  <arm_group>
    <arm_group_label>Litx + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talaporfin sodium</intervention_name>
    <description>LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).</description>
    <arm_group_label>Litx + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous placement of device in liver metastases</intervention_name>
    <description>Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.</description>
    <arm_group_label>Litx + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interstitial light emitting diodes</intervention_name>
    <description>200 J/cm per Light Source at 20 mW/cm light energy</description>
    <arm_group_label>Litx + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX4 regimen</intervention_name>
    <description>Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin</description>
    <arm_group_label>Litx + Chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
    <description>Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan</description>
    <arm_group_label>Litx + Chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with recurrent metastatic liver lesions from colorectal cancer who progressed
             on either FOLFOX or FOLFIRI

          -  Biopsy proven evidence of colorectal cancer

          -  At least one liver lesion that can be measured in one dimension at &gt;10 mm with spiral
             CT scan (CT preferred but MRI allowed)

          -  ECOG Performance Status 0-2

          -  Life expectancy of at least 16 weeks

          -  At least 30 days must have elapsed since the completion of any prior antineoplastic
             therapy and the patient must have recovered from acute side effects before day 0

          -  Understanding and ability to sign written informed consent

          -  18 years of age or more

          -  Adequate hematologic, liver and renal functions as evidenced by the following: WBC &gt;
             2.5 × 10^9/L ; Platelet Count &gt; 100 × 10^9/L ; Hemoglobin &gt; 90 g/L ; Neutrophils &gt;1.5
             × 10^9/L ; PT and PTT &lt; 1.5 Control ; SGOT, SGPT &lt; 5 × ULN ; GGT &lt; 5 × ULN ; Alkaline
             phosphatase &lt; 5 × ULN ; Bilirubin &lt; 3 × ULN ; Creatinine &lt; 1.5 × ULN

        Exclusion Criteria:

          -  Patients who are candidates for complete surgical resection

          -  Patients who received bevacizumab (Avastin®) or cetuximab (Erbitux®) within 30 days of
             randomization. Use of bevacizumab or cetuximab is prohibited while participating in
             this study

          -  Patients who would require more than a total number of 12 light source applications
             over three Litx™ experimental treatments (no more than 4 light sources per treatment).

          -  Patients who have a single measurable tumor greater than 7.5 cm in any organ

          -  Target lesions irradiated within 3 months of randomization

          -  Patients with tumor involvement in greater than 50% of parenchyma of the liver

          -  Evidence of major vessel invasion of any organ

          -  Patients with any non-colorectal cancers except for adequately treated basal or
             squamous cell skin cancer, or adequately treated stage I or II cancer from which the
             patient has been disease-free for ≥ 3 years, or other cancer from which the patient
             has been disease-free for ≥ 5 years

          -  Known sensitivity to porphyrin-type drugs or known history of porphyria

          -  Pregnancy or breast-feeding patients. A negative pregnancy test (urine or serum) from
             women of childbearing age is required prior to enrollment. A fertile patient must use
             effective contraception during participation in the study

          -  Concurrent participation in another clinical trial involving experimental treatment

          -  Any concurrent disease or condition that in the opinion of the investigator impairs
             the patient's ability to complete the trial such as psychological, familial,
             sociological, geographical or medical conditions which in the Principal Investigator's
             opinion could compromise compliance with the objectives and procedures of this
             protocol or obscure interpretation of the trial's data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sy-Shi Wang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Light Sciences Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hietzing mit Neurologischen Zentrum Rosenhugel</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Mostar, Internal Clinic, Department of Gastroenterology</name>
      <address>
        <city>Mostar</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of the University of Sarajevo, Institute of Oncology</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Karlovac</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Zagreb, Clinical Oncology</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Sveti Duh&quot;</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostalb-Klinikum Aalen Darmzentrum Medizinische Klinik I</name>
      <address>
        <city>Aalen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken - Innere Medizin und Kardiologie</name>
      <address>
        <city>Borna</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Krankenhaus St. Johann Nepomuk</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe Universitat</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Ludwigsburg Bietigheim</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahavir Cancer Sansthan</name>
      <address>
        <city>Phulwarisharif</city>
        <state>Patna</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIIGMA Institute of Medical Sciences</name>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Nehru Cancer Hospital and Research Centre</name>
      <address>
        <city>Bhopal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SEAROC Cancer Center, S. K. Soni hospital</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shatabdi Super Specialty Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Clinic, Shreevardhan complex</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Riunti</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Careggi U.O. Oncologia Medica</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Padovana</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata - Oncologia Medica</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga Eastern Hospital, Latvian Oncology Center</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Skłodowskiej -Curie Oddział w Krakowie</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki CMUJ, Klinika Chirurgii Ogólnej i Gastroenterologicznej</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chirurgii Onkologicznej</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zakład Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chirurgii Ogólnej i Onkologicznej</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Skłodowskiej -Curie, Klinika Nowotworów Jelita Grubego</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki im. M. Kopernika, Klinika Chemioterapii Onkologicznej</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute &quot;Ion Chircuta&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Spiridon University Emergency Hospital</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Altay&quot; Territorial Oncological Dispensary</name>
      <address>
        <city>Barmaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Sverdlovsk' Regional Oncological Dispensary&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Main Military Clinical Hospital named after Burdenko attached to Ministry of Defense of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Cliical Hospital # 33 named after Ostroumov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncological Scientific Center named after Blokhin</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privolzhsky District Medical Center</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Research Institute of Roentgenology and Radiology</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institution of Oncology</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of High Professional Education &quot;Military-Medical Academy named after S.M. Kirov attached to Ministry of Defense of Russia&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tambov Regional Oncological Dispensary</name>
      <address>
        <city>Tambov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Yaroslavl region, &quot;Regional clinical oncological hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Cherkassy&quot; Regional Oncological Dispensary of Cherkassy</name>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Multiple-Discipline Clinical Hospital #4</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk Cancer Centre</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkov Regional Clinical Oncology Dispansery</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of the Ministry of Defense</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporozhye Medical Academy for postgraduate education</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bosnia and Herzegovina</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
    <country>Slovakia</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2007</study_first_submitted>
  <study_first_submitted_qc>February 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <results_first_submitted>July 28, 2015</results_first_submitted>
  <results_first_submitted_qc>July 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2015</results_first_posted>
  <disposition_first_submitted>January 9, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>January 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 22, 2015</disposition_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver neoplasms</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>MCRC</keyword>
  <keyword>Litx™</keyword>
  <keyword>LS11</keyword>
  <keyword>Colorectal cancer with recurrent liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasm Recurrence, Local</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Talaporfin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Litx + Chemotherapy</title>
          <description>Talaporfin sodium: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
Percutaneous placement of device in liver metastases: Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
Interstitial light emitting diodes: 200 J/cm per Light Source at 20 mW/cm light energy
FOLFOX4 regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
FOLFIRI regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan</description>
        </group>
        <group group_id="P2">
          <title>Chemotherapy Alone</title>
          <description>FOLFOX4 regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
FOLFIRI regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="216"/>
                <participants group_id="P2" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Reply at EOS</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Status Unknown</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients randomized/enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Litx + Chemotherapy</title>
          <description>Talaporfin sodium: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
Percutaneous placement of device in liver metastases: Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
Interstitial light emitting diodes: 200 J/cm per Light Source at 20 mW/cm light energy
FOLFOX4 regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
FOLFIRI regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan</description>
        </group>
        <group group_id="B2">
          <title>Chemotherapy Alone</title>
          <description>FOLFOX4 regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
FOLFIRI regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="244"/>
            <count group_id="B2" value="239"/>
            <count group_id="B3" value="483"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="9.8"/>
                    <measurement group_id="B2" value="60.1" spread="10.2"/>
                    <measurement group_id="B3" value="59.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" lower_limit="20" upper_limit="83"/>
                    <measurement group_id="B2" value="61.0" lower_limit="31" upper_limit="81"/>
                    <measurement group_id="B3" value="60.0" lower_limit="20" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Time from randomization to death</description>
        <time_frame>Up to 184 weeks</time_frame>
        <population>ITT (All patient randomized/enrolled)</population>
        <group_list>
          <group group_id="O1">
            <title>Litx + Chemotherapy</title>
            <description>Talaporfin sodium: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
Percutaneous placement of device in liver metastases: Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
Interstitial light emitting diodes: 200 J/cm per Light Source at 20 mW/cm light energy
FOLFOX4 regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
FOLFIRI regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Alone</title>
            <description>FOLFOX4 regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
FOLFIRI regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from randomization to death</description>
          <population>ITT (All patient randomized/enrolled)</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390" lower_limit="234" upper_limit="735"/>
                    <measurement group_id="O2" value="405" lower_limit="244" upper_limit="655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Litx + Chemotherapy</title>
          <description>Talaporfin sodium: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
Percutaneous placement of device in liver metastases: Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
Interstitial light emitting diodes: 200 J/cm per Light Source at 20 mW/cm light energy
FOLFOX4 regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
FOLFIRI regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan</description>
        </group>
        <group group_id="E2">
          <title>Chemotherapy Alone</title>
          <description>FOLFOX4 regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
FOLFIRI regimen: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Haemobilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Metastases to perineum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Malignant tumour excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Eastern cooperative oncology group performance status worsened</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Catheterisation venous</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President of Regulatory Affairs and Clinical Operations</name_or_title>
      <organization>Light Sciences Oncology, Inc.</organization>
      <phone>425-957-8986</phone>
      <email>lisak@lsoncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

